Recognition highlights the hospital network’s decade-long investment in analytics and AI-driven healthcare, supporting improved outcomes, efficiency, and affordability.
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
